BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation

Reuters

2025/11/22

<a href="https://laohu8.com/S/BRTX">BioRestorative Therapies</a> Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation

BioRestorative Therapies Inc. has released a new investor presentation detailing its progress as a fully integrated regenerative medicine company. The presentation outlines the company's development pipeline, which includes mid-stage clinical programs using bone marrow-derived mesenchymal stem cells (BRTX-100) and preclinical research on brown adipose-derived stem cells (ThermoStem). The company is also advancing biologics-based cosmetic products, including secretome technologies for aesthetic applications, with an exclusive five-year commercial agreement with Cartessa Aesthetics. Key market opportunities highlighted include the global cosmetic and injectable markets, supported by the company's cGMP ISO 7 certified manufacturing facility and expertise in cellular biology engineering. The presentation also notes ongoing Phase 2 clinical trials targeting musculoskeletal conditions. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2585122616"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585122616\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585122616?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-22 08:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585122616","market":"nz","top_or_hot":-1,"title":"BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BRTX\">BioRestorative Therapies</a> Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioRestorative Therapies Inc. has released a new investor presentation detailing its progress as a fully integrated regenerative medicine company. The presentation outlines the company's development pipeline, which includes mid-stage clinical programs using bone marrow-derived mesenchymal stem cells (BRTX-100) and preclinical research on brown adipose-derived stem cells (ThermoStem). The company is also advancing biologics-based cosmetic products, including secretome technologies for aesthetic applications, with an exclusive five-year commercial agreement with Cartessa Aesthetics. Key market opportunities highlighted include the global cosmetic and injectable markets, supported by the company's cGMP ISO 7 certified manufacturing facility and expertise in cellular biology engineering. The presentation also notes ongoing Phase 2 clinical trials targeting musculoskeletal conditions. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-22 08:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BRTX\">BioRestorative Therapies</a> Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioRestorative Therapies Inc. has released a new investor presentation detailing its progress as a fully integrated regenerative medicine company. The presentation outlines the company's development pipeline, which includes mid-stage clinical programs using bone marrow-derived mesenchymal stem cells (BRTX-100) and preclinical research on brown adipose-derived stem cells (ThermoStem). The company is also advancing biologics-based cosmetic products, including secretome technologies for aesthetic applications, with an exclusive five-year commercial agreement with Cartessa Aesthetics. Key market opportunities highlighted include the global cosmetic and injectable markets, supported by the company's cGMP ISO 7 certified manufacturing facility and expertise in cellular biology engineering. The presentation also notes ongoing Phase 2 clinical trials targeting musculoskeletal conditions. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251122:nNDL4XrrZs:1","article_id":"2585122616","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585122616","pubTimestamp":1763771364,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioRestorative Therapies Inc. has released a new investor presentation detailing its progress as a fully integrated regenerative medicine company. The presentation outlines the company's development pipeline, which includes mid-stage clinical programs using bone marrow-derived mesenchymal stem cells  and preclinical research on brown adipose-derived stem cells . The company is also advancing biologics-based cosmetic products, including secretome technologies for aesthetic applications, with an exclusive five-year commercial agreement with Cartessa Aesthetics. Key market opportunities highlighted include the global cosmetic and injectable markets, supported by the company's cGMP ISO 7 certified manufacturing facility and expertise in cellular biology engineering. The presentation also notes ongoing Phase 2 clinical trials targeting musculoskeletal conditions. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BRTX":"BioRestorative Therapies, Inc."},"translate_title":"BioRestorative Therapies Inc.在新的投资者介绍中公布了再生医学管道和商业计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRTX":0.9},"content_text":"BioRestorative Therapies Inc. unveils regenerative medicine pipeline and commercial plans in new investor presentation\n    \n\n        BioRestorative Therapies Inc. has released a new investor presentation detailing its progress as a fully integrated regenerative medicine company. The presentation outlines the company's development pipeline, which includes mid-stage clinical programs using bone marrow-derived mesenchymal stem cells (BRTX-100) and preclinical research on brown adipose-derived stem cells (ThermoStem). The company is also advancing biologics-based cosmetic products, including secretome technologies for aesthetic applications, with an exclusive five-year commercial agreement with Cartessa Aesthetics. Key market opportunities highlighted include the global cosmetic and injectable markets, supported by the company's cGMP ISO 7 certified manufacturing facility and expertise in cellular biology engineering. The presentation also notes ongoing Phase 2 clinical trials targeting musculoskeletal conditions. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}